Chronic Beryllium Disease
| Autor: | Margaret M. Mroz, Daniel A. Culver, Maeve G. MacMurdo, Lisa A. Maier, Raed A. Dweik |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Pulmonary and Respiratory Medicine
Permissible exposure limit business.industry Medical screening Beryllium exposure chemistry.chemical_element Critical Care and Intensive Care Medicine medicine.disease Lymphocyte proliferation test Occupational safety and health respiratory tract diseases 03 medical and health sciences 0302 clinical medicine 030228 respiratory system chemistry Environmental health medicine 030212 general & internal medicine Beryllium Occupational lung disease Cardiology and Cardiovascular Medicine business Beryllium Disease |
| Zdroj: | Chest. 158:2458-2466 |
| ISSN: | 0012-3692 |
| Popis: | Beryllium exposure remains an ongoing occupational health concern for workers worldwide. Since the initial Occupational Safety and Health Administration (OSHA) ruling on a permissible exposure limit (PEL) for beryllium in 1971, our understanding of the risks of beryllium sensitization and chronic beryllium disease (CBD) has evolved substantially. A new OSHA ruling released in early 2017 and implemented in late 2018 reduced the PEL for beryllium, increased requirements for medical screening and monitoring, and may ultimately enhance worker protection. This review highlights advances in our understanding of the pathway from beryllium exposure to sensitization and progression to CBD that guided the development of this OSHA ruling. Screening workers exposed to beryllium and management of CBD will also be discussed. Finally, we will discuss the role of beryllium as a cause of morbidity and mortality among exposed workers in this potentially preventable occupational lung disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|